My Treatment Approach: Optimizing Care for Relapsed / Refractory Multiple Myeloma: Translating Evidence to Clinical Practice - Episode 6

Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

August 28, 2024

Robert Z. Orlowski, MD, PhD, Jonathan L. Kaufman, MD

The panel evaluates selinexor's current role in the treatment landscape for multiple myeloma and explores its potential future applications and evolving significance in therapeutic strategies.

EP. 1: Clinical Scenario I: 68-yr Old Man with Early Relapse MM

EP. 2: Clinical Insights on Next Treatment Approach Steps

EP. 3: Real Life Clinical Practice Use of Selinexor: Dosing Strategies, Supportive Care, and Strategies to Incorporate into Novel Selinexor-Based Regimens

EP. 4: Expert Perspectives: Navigating the Evolving Treatment Landscape in Early Relapse MM

EP. 5: Overview of CAR T-cell Therapy Options in R/R MM

Now Viewing

EP. 6: Expert Perspectives: Selinexor Role in the Changing Treatment Landscape in MM and Key Takeaways

EP. 7: Patient Profile: 53-Year-Old Man with Heavily Pre-Treated MM including T-cell Directed Therapy

EP. 8: Clinical Insights on the Patient Presentation & Treatment Course

EP. 9: Challenges of Treatment Sequencing in Heavily Pre-Treated R/R MM: Expert Insights

EP. 10: Potential Novel Lab Monitoring & Key Takeaways for Heavily Pre-Treated R/R MM

EP. 11: Clinical Pearls & Unmet Needs in Early and Late Relapse R/R MM

Video content above is prompted by the following:

As the myeloma treatment landscape constantly evolves, where do you see selinexor fitting in? How might the future use of selinexor change?
What are some key takeaways you can offer community colleagues? How can community oncologists partner with academic clinicians for patient identification and treatment?